Femma5 is developing an artificial pancreas called Femma5 Insulin Dosage Assistant that automatically regulates insulin levels based on continuous glucose monitoring, eliminating the need for finger pricks and manual insulin dosing calculations. They are seeking investors to fund clinical trials of the device and development of a holistic diabetes management platform. The company's team has extensive experience in diabetes care, medical device R&D and manufacturing, and commercializing healthcare products.

1. We are now in the process to find out partners interested
in investing 1) in the clinical trial program and the parallel
development of an artificial pancreas system with select-
ed industrial partners and holistic Diabetes Management
System with Finnish leading hospitals and 2) in the com-
mercialization and global distribution of the final products.
Our team is consisting of experienced professionals with
proven track record in diabetes care with special expe-
rience in insulin pump therapy, R&D and manufacturing of
IVD products, measurement science technology and pro-
gramming, industrial design, commercialization and sales
& marketing of health care products.
The invention of Femma5, an artificial pancreas,
“Femma5 Insulin Dosage Assistant”, is based on
three years of testing and development work of Mr
Mika Bäckström, PhD, type 1 diabetic and one of the
co-founders of the company Femma5 Ltd.
Femma5 Insulin Dosage Assistant is a unique product re-
leasing people with diabetes from daily self care routines:
no need to make daily finger pricking, no need to estimate
carbohydrates, no need to calculate insulin doses. It is a
semi-automatic closed
loop artificial pancreas
system with an option to
be used as a real closed
loop.
The working research
prototype is based on the
use of a commercial con-
tinuous glucose monitor
and an insulin pump. It
is ready for clinical trials.
Femma5 is not only developing an Insulin Dosage Assis-
tant but also a mHealth online platform needed to develop
a holistic, patient centric, diabetes management solution
for the joint use of diabetic people and medical staff. We
have identified the needed resources and existing platform
in order to develop a testing version in a short period of
time. The major benefits of Diabetes Management Soluti-
on for stakeholders are: easier self care, improved safety
and quality of life (people with diabetes), better glucose
balance, glycemic control and treatment effectivity (people
with diabetes and medical staff), better cost efficiency (ca-
regivers and payers).
Our goal is to make needed clinical trials in close collabo-
ration with two leading Finnish University Hospitals and to
develop together with them a Disease Management Solu-
tion for routine use fitting both type 1 and type 2 diabetic
people.
Femma5 Ltd, Kuortaneenkatu 2, 00510 Helsinki; www.femma5.com; petteri.venetjoki@femma5.com; +358 40 848 7312
”It was a challenging task to take care of diabetes. It was stressful.
Our solution is like a miracle! Mika Bäckström, Co-founder, 2015
No more finger pricking
No more estimation of carbohydrates and in-
sulin boluses
We have skills but we need investors
Strong and diverse team
Holistic solution for diabetes
management
Clinical Trials
Mika Bäckström,Co-founder, Ph.D. (Tech.),
has a long experience of measurement
science technology and programming.
Petteri Venetjoki, CEO, Co-founder, M.A.,
Expert on strategic and practical design of
products and services.
Markku Pohjola, Partner, M.Sc. (Bioche-
mistry), 35 years of working history in leading
positions of listed and start up health care
companies in the areas of in vitro diagnostics,
diabetes and oncology.
Veli Hänninen, Partner, M.Sc. (Bioche-
mistry,Radiochemistry) Expert on R&D
and manufacturing of IVD industry. He has
successfully commercialized plenty of IVD
products.
Mikko Honkasalo, Partner, M.D.Ph.D, Long
practical experience on diabetes care inclu-
ding insulin pump therapy and continuous
glucose monitoring. Expert on quality and
cost comparison of diabetes care in primary
health care.
Marcus Westermark, IT Specialist, M.Sc.
Expert in medical device and ICT system
design. Has worked recently in developing
cloud-based diabetes software solutions.
Type 1 diabetic.
For better diabetes care
Sergey Sedelnikov, IT Specialist, M.Sc.
Medical software development, CE and FDA
medical software validation. Web and Windo-
ws application development, cloud computing
UI and Backend Test automation.